Recent Press Releases

Celgene and Juno Announce Ten-Year Collaboration to Advance Potentially Groundbreaking Immunotherapies for Patients with Cancer and Autoimmune Diseases

Broad strategic collaboration leveraging combined immunology expertise and assets to develop and commercialize novel immunotherapies for the treatment of cancer and autoimmune diseases Celgene...

Immune Pharmaceuticals Signs License & Research Agreement for AmiKet™ Nano

PR Newswire Immune Pharmaceuticals Inc.  NEW YORK, June 29, 2015 /PRNewswire/ -- Immune Pharmaceuticals Inc. (IMNP) announced today that it has entered into a definitive license and research...

Actelion creates Vaxxilon together with the Max Planck Society

ALLSCHWIL, SWITZERLAND - 26 June 2015 - Actelion Ltd (SIX: ATLN) today announced the creation of a start-up, together with the Max Planck Society, in the field of synthetic carbohydrate vaccines....

Lilly and Immunocore Announce Immunotherapy-based Clinical Trial Collaboration in Melanoma

INDIANAPOLIS and OXFORD, England, June 29, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Immunocore Limited today announced that they have entered into an immunotherapy-based clinical...

Egalet Announces Positive Top-Line Results from Intranasal Human Abuse Liability Study of Abuse-Deterrent Morphine, Egalet-001

WAYNE, Pa., June 29, 2015 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet") today announced positive results from a Category 3 intranasal human abuse liability (HAL) study of...

Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy

Merck (MRK), known as MSD outside the United States and Canada, today announced results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND® (fosaprepitant...

Spinifex Pharmaceuticals to be Acquired by Novartis

Spinifex Pharmaceuticals to be Acquired by Novartis STAMFORD, Connecticut and MELBOURNE, Australia, June 29, 2015 /PRNewswire/ -- US$200 million upfront payment plus undisclosed clinical...

Aduro Biotech Announces Immunotherapy Regimen Successfully Passes Futility Analysis in Phase 2b ECLIPSE Trial in Metastatic Pancreatic Cancer

Aduro Biotech Announces Immunotherapy Regimen Successfully Passes Futility Analysis in Phase 2b ECLIPSE Trial in Metastatic Pancreatic Cancer Enrollment on Track for Completion of Primary Cohort in...

Sarepta Therapeutics Completes NDA Submission to FDA for Eteplirsen for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

CAMBRIDGE, Mass.--(--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced the completion of the rolling submission of a New Drug Application...

Spinifex Pharmaceuticals to be Acquired by Novartis

US$200 million upfront payment plus undisclosed clinical development and regulatory milestones Expands Novartis' neuroscience portfolio with novel angiotensin II type 2 receptor antagonist...

Adocia and Lilly report positive Phase 1b topline results on the post-meal effect of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes

Adocia (Paris:ADOC) (Euronext Paris : ADOC) and Eli Lilly and Company (NYSE: LLY) announced today the completion of a Phase 1b clinical trial evaluating BioChaperone Lispro, an ultra-rapid...

Venture Financing in Biotech Follows Male CEOs and Boards

Only 5.4% of venture capital invested in biotechnology companies with women CEOs Biotechnology companies with all-male boards garner 57% of all venture financing Women just 3% of new CEO...

Alexion Receives CHMP Positive Opinions for Strensiq™ (asfotase alfa) and Kanuma™ (sebelipase alfa) in the European Union

- CHMP Recommends Marketing Authorization for Strensiq for Patients with Pediatric-Onset HPP - - CHMP Recommends Marketing Authorization for Kanuma for Patients of all Ages with LAL-d - CHESHIRE,...

Alexandria Real Estate Equities, Inc. Announces 15-Year Anchor Lease of 208,000 RSF with Bristol-Myers Squibb at 100 Binney Street at the Alexandria Center® at Kendall Square in Cambridge, MA

PASADENA, Calif., June 26, 2015 /PRNewswire/ -- Alexandria Real Estate Equities, Inc. (NYSE: ARE), the largest and leading REIT uniquely focused on collaborative science campuses in urban innovation...

ProNAi Therapeutics, Inc. Appoints Dr. Barbara Klencke As Chief Development Officer

VANCOUVER, June 23, 2015 /PRNewswire/ - ProNAi Therapeutics Inc., a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today...

Kryptiq Introduces New Chief Medical Officer, Joseph Siemienczuk, MD

BEAVERTON, Ore., June 23, 2015 /PRNewswire/ -- Kryptiq, a market leader in population health management, announced today the appointment of Joseph Siemienczuk, MD, as its chief medical officer. In...

Charlie Barker Named Director Of Scientific Services At SNBL USA

EVERETT, Wash.--(BUSINESS WIRE)--SNBL USA, the experts in preclinical research, today announced Charlie Barker has joined the executive team to serve as the Director of Scientific Services. In this...

TissueGen, Inc. Appoints Dr. Jennifer Seifert As Senior Scientist To Lead Spinal Cord Injury Repair Program

TissueGen® Inc., developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, today announced that Jennifer Seifert, Ph.D., has joined the company in the...

Ambrx, Inc. Names Dr. Tiecheng Qiao As CEO, Dr. Feng Tian As CSO

SAN DIEGO, June 19, 2015 /PRNewswire/ -- Ambrx, Inc., a clinical stage biotechnology company that discovers and develops first-in-class and best-in-class optimized protein therapeutics known as...

Ultragenyx Pharmaceuticals (RARE) Appoints Jayson Dallas, M.D., As Chief Commercial Officer And Senior Vice President

NOVATO, Calif., June 22, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...